DKK-1 in prostate cancer diagnosis and follow up

BMC Clinical Pathology

Giovanni Carlo Isaia¹  Paolo Gontero³  Giulio Mengozzi⁴  Riccardo Ferracini²  Andrea Zitella³  Francesco Soria³  Marco Oderda³  Ilaria Roato⁵  Patrizia D’Amelio¹ 

[1] Gerontology Section, Department of Medical Sciences, University of Torino, Corso Bramante 88/90, 10126 Torino, Italy;Department of Orthopedics, Hospital City of Health and Science of Turin, Turin, Italy;Urology Section, Department of Surgical Science, Hospital City of Health and Science of Turin, University of Turin, Turin, Italy;Baldi & Riberi Lab, Hospital City of Health and Science of Turin, Turin, Italy;Center for Research in Experimental Medicine (CeRMS), Hospital City of Health and Science of Turin, Turin, Italy

关键词: Bone metastases;    DKK-1;    Dickoppf-1;    PSA;    Prostate cancer;   

Others  :  821459
DOI  :  10.1186/1472-6890-14-11

 received in 2013-07-23, accepted in 2014-03-10,  发布年份 2014

【 摘 要 】

Background

Dickoppf-1 (DKK-1) is a negative regulator of bone formation with tumorigenic potential. The up-regulation of DKK-1 is an early event in prostate cancer (PCa) development, thus we investigated its role as a marker in the diagnosis and prognosis of PCa.

Methods

We retrospectively enrolled 159 patients who underwent prostate biopsy, either for elevated PSA or suspect digital rectal examination, between 2003 and 2010. During the biopsy, one serum sample was collected from all patients; PSA and DKK-1 were measured by ELISA technique. Amongst the biopsy of 159 patients 75 were affected by PCa and 84 were not the mean period of follow-up for these patients was 5 years; a new biopsy was performed in case of PCa suspicion.

Results

PSA performed better than DKK-1 in detecting PCa (0.63 vs 0.51 respectively). Differently from PSA DKK-1 was significantly higher in patients who developed PCa during follow-up than in cancer-free ones, thus DKK-1 performed better than PSA in detecting these patients (0.67 vs 0.55). DKK-1 was significantly lower in patients with bone metastases, whereas PSA was not significantly different in patients with different outcomes.

Conclusions

DKK-1 might be predictive for patients negative at first biopsy who will develop PCa and in the prognosis of bone metastases. It performed worse than PSA in the early diagnosis of Pca.

【 授权许可】

   
2014 D’Amelio et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of Urology: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59(1):61-71.
• [2]Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004, 350(22):2239-2246.
• [3]Bantis A, Grammaticos P: Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased? Hell J Nucl Med 2012, 15(3):241-246.
• [4]Gomceli I, Bostanci EB, Ozer I, Kemik AS, Turhan N, Tez M, Kilic S, Demiriz B, Akoglu M: A novel screening biomarker in gastric cancer: serum dickkopf-1. Hepatogastroenterology 2012, 59(117):1661-1664.
• [5]Jiang T, Wang S, Huang L, Zhang S: Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer 2009, 19(7):1177-1181.
• [6]Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem 2009, 55(9):1656-1664.
• [7]Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P, Garnero P: Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97(7):964-970.
• [8]Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, et al.: Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007, 67(6):2517-2525.
• [9]Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349(26):2483-2494.
• [10]Manolagas SC, Almeida M: Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007, 21(11):2605-2614.
• [11]Daoussis D, Andonopoulos AP: The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 2011, 41(2):170-177.
• [12]Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ: Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 2011, 71(6):615-625.
• [13]Menezes ME, Devine DJ, Shevde LA, Samant RS: Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 2012, 130(7):1477-1483.
• [14]Zhang Y, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, Millar S, Hoey T, Hebrok M, Pasca di Magliano M: Canonical Wnt signaling Is required for pancreatic carcinogenesis. Cancer Res 2013, 73(15):4909-4922.
• [15]Emami KH, Corey E: When prostate cancer meets bone: control by wnts. Cancer Lett 2007, 253(2):170-179.
• [16]Guo Y, Guo W, Chen Z, Kuang G, Yang Z, Dong Z: Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma. Neoplasma 2011, 58(2):110-117.
• [17]Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET: Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005, 65(17):7554-7560.
• [18]Roato I, D’Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R: Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 2008, 3(11):e3627.
• [19]Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C: Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 2013, 73(9):932-940.
• [20]Ilic D, Neuberger MM, Djulbegovic M, Dahm P: Screening for prostate cancer. Cochrane Database Syst Rev 2013., 1CD004720
• [21]Vasarainen H, Malmi H, Maattanen L, Ruutu M, Tammela T, Taari K, Rannikko A, Auvinen A: Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC). Acta Oncol 2013, 52(8):1615-1621.
• [22]Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001, 20(3–4):333-349.
• [23]Hall CL, Keller ET: The role of Wnts in bone metastases. Cancer Metastasis Rev 2006, 25(4):551-558.
• [24]Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET: Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008, 68(13):1396-1404.
• [25]Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, Ishikawa N, Kohno N, Ito H, Miyamoto M, Nakayama H, Miyagi Y, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y: Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010, 70(13):5326-5336.
• [26]Lee HS, Lee HE, Park do J, Kim HH, Kim WH, Park KU: Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta 2012, 413(21–22):1753-60.
• [27]Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W: Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012, 13(8):817-826.
• [28]Tung EK, Ng IO: Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma. Future Oncol 2012, 8(12):1525-1528.
• [29]Yao X, Jiang H, Zhang C, Wang H, Yang L, Yu Y, Yu J, Shi B, Shen Z, Gao H, Chen Z, Tian S, Lu S, Li Z, Gu J: Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer. Biomarkers 2010, 15(2):128-134.
• [30]Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597.